8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 17, 2026·SEC
Neuronetics, Inc.(STIM)Earnings, Financials & Key Ratios
STIM•NASDAQ
$1.91
$133M mkt cap·Price updated May 6, 2026
AboutNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Show more
- Revenue$149M+99.2%
- EBITDA-$28M+13.9%
- Net Income-$39M+10.8%
- EPS (Diluted)-0.59+57.2%
- Gross Margin48.48%-33.0%
- EBITDA Margin-18.75%+56.8%
- Operating Margin-21.08%+54.3%
- Net Margin-26.15%+55.2%
- ROE-134.39%-1.4%
- ROIC-26.58%+32.3%
- Debt/Equity3.44+32.4%
- Interest Coverage-3.74+25.3%
STIM Key Insights
Neuronetics, Inc. (STIM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 24.8%
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗High debt to equity ratio of 3.4x
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
STIM Price & Volume
Neuronetics, Inc. (STIM) stock price & volume — 10-year historical chart
Loading chart...
STIM Growth Metrics
Neuronetics, Inc. (STIM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years24.81%
3 Years31.76%
TTM69.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.78%
Return on Capital
10 Years-40.44%
5 Years-31.72%
3 Years-32.04%
Last Year-28.49%
STIM Recent Earnings
Neuronetics, Inc. (STIM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$0.16
Est $0.17
+5.9%
Revenue
$34M
Est $34M
+0.8%
Q2 2026
Mar 17, 2026EPS
$0.10
Est $0.12
+16.7%
Revenue
$42M
Est $41M
+2.7%
Q4 2025
Nov 4, 2025EPS
$0.13
Est $0.12
-8.3%
Revenue
$37M
Est $38M
-1.5%
Q3 2025
Aug 5, 2025EPS
$0.15
Est $0.08
-87.5%
Revenue
$38M
Est $38M
+0.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.16vs $0.17+5.9% | $34Mvs $34M+0.8% |
| Q2 2026 | Mar 17, 2026 | $0.10vs $0.12+16.7% | $42Mvs $41M+2.7% |
| Q4 2025 | Nov 4, 2025 | $0.13vs $0.12-8.3% | $37Mvs $38M-1.5% |
| Q3 2025 | Aug 5, 2025 | $0.15vs $0.08-87.5% | $38Mvs $38M+0.7% |
Based on last 12 quarters of dataView full earnings history →
STIM Peer Comparison
Neuronetics, Inc. (STIM) competitors in Diagnostic Imaging Systems and Services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ELMD | 214.77M | 25.94 | 30.16 | 16.97% | 13.06% | 19.79% | 0.00 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ABSI | 924.91M | 5.95 | -7.08 | -38.24% | -41.14% | -59.68% | 0.03 | |
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 GKOS | 7.92B | 135.27 | -41.24 | 32.33% | -34.34% | -26.46% | 0.21 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 |
Compare STIM vs Peers
Neuronetics, Inc. (STIM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STIM Income Statement
Neuronetics, Inc. (STIM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 40.43M | 52.78M | 62.66M | 49.24M | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M | 151.64M |
| Revenue Growth % | 18.13% | 30.53% | 18.72% | -21.41% | 12.32% | 17.89% | 9.42% | 4.96% | 99.17% | 69.52% |
| Cost of Goods Sold | 9.63M | 12.45M | 15.39M | 11.55M | 11.65M | 15.48M | 19.64M | 20.73M | 76.85M | 78.91M |
| COGS % of Revenue | 23.82% | 23.58% | 24.56% | 23.46% | 21.07% | 23.74% | 27.53% | 27.68% | 51.52% | - |
| Gross Profit | 30.8M▲ 0% | 40.33M▲ 30.9% | 47.27M▲ 17.2% | 37.69M▼ 20.3% | 43.66M▲ 15.8% | 49.72M▲ 13.9% | 51.7M▲ 4.0% | 54.16M▲ 4.8% | 72.31M▲ 33.5% | 72.72M▲ 0% |
| Gross Margin % | 76.18% | 76.42% | 75.44% | 76.54% | 78.93% | 76.26% | 72.47% | 72.32% | 48.48% | 47.96% |
| Gross Profit Growth % | 11.57% | 30.93% | 17.2% | -20.26% | 15.84% | 13.89% | 3.99% | 4.75% | 33.51% | - |
| Operating Expenses | 44.41M | 60.16M | 74.2M | 60M | 71.22M | 84.83M | 82.26M | 88.72M | 103.74M | 102.14M |
| OpEx % of Revenue | 109.83% | 114% | 118.42% | 121.84% | 128.77% | 130.1% | 115.29% | 118.47% | 69.55% | - |
| Selling, General & Admin | 36.47M | 51.93M | 60.45M | 50.8M | 63.3M | 75.5M | 72.74M | 75.95M | 97.16M | 95.81M |
| SG&A % of Revenue | 90.2% | 98.4% | 96.48% | 103.16% | 114.44% | 115.78% | 101.96% | 101.42% | 65.14% | - |
| Research & Development | 7.94M | 8.23M | 13.75M | 9.2M | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M | 6.33M |
| R&D % of Revenue | 19.63% | 15.6% | 21.94% | 18.68% | 14.32% | 14.32% | 13.34% | 17.05% | 4.41% | - |
| Other Operating Expenses | 357K | -575K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.61M▲ 0% | -19.83M▼ 45.8% | -26.93M▼ 35.8% | -22.31M▲ 17.2% | -27.56M▼ 23.6% | -35.11M▼ 27.4% | -30.55M▲ 13.0% | -34.56M▼ 13.1% | -31.44M▲ 9.0% | -29.42M▲ 0% |
| Operating Margin % | -33.66% | -37.58% | -42.98% | -45.3% | -49.83% | -53.85% | -42.82% | -46.15% | -21.08% | -19.4% |
| Operating Income Growth % | -45.74% | -45.75% | -35.78% | 17.16% | -23.56% | -27.38% | 12.98% | -13.12% | 9.05% | - |
| EBITDA | -12.94M | -18.95M | -25.86M | -21.37M | -26.5M | -33.46M | -28.55M | -32.49M | -27.97M | -26.86M |
| EBITDA Margin % | -31.99% | -35.91% | -41.28% | -43.39% | -47.92% | -51.32% | -40.01% | -43.38% | -18.75% | -17.72% |
| EBITDA Growth % | -49.3% | -46.52% | -36.48% | 17.39% | -24.04% | -26.26% | 14.69% | -13.81% | 13.91% | 25.99% |
| D&A (Non-Cash Add-back) | 673K | 882K | 1.06M | 941K | 1.06M | 1.65M | 2.01M | 2.07M | 3.46M | 2.55M |
| EBIT | -13.25M | -20.41M | -28.26M | -26.83M | -27.87M | -33.61M | -24.77M | -36.44M | -31.44M | -20.48M |
| Net Interest Income | -2.81M | -3.69M | -3.69M | -4.52M | -3.3M | -3.6M | -5.4M | -7.3M | -8.41M | -6.15M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 24K | 0 | 0 | 0 |
| Interest Expense | 2.81M | 3.69M | 3.69M | 4.52M | 3.3M | 3.6M | 5.42M | 7.29M | 8.41M | 8.41M |
| Other Income/Expense | -2.45M | -4.26M | -2.11M | -5.14M | -3.61M | -2.1M | 365K | -9.18M | -7.56M | -7.83M |
| Pretax Income | -16.06M▲ 0% | -24.1M▼ 50.1% | -29.04M▼ 20.5% | -27.45M▲ 5.5% | -31.17M▼ 13.6% | -37.21M▼ 19.4% | -30.19M▲ 18.9% | -43.74M▼ 44.9% | -39M▲ 10.8% | -37.25M▲ 0% |
| Pretax Margin % | -39.72% | -45.66% | -46.35% | -55.75% | -56.36% | -57.06% | -42.31% | -58.41% | -26.15% | -24.56% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -24K | -14K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0.08% | 0.03% | 0% | 0% |
| Net Income | -16.06M▲ 0% | -24.1M▼ 50.1% | -29.04M▼ 20.5% | -27.45M▲ 5.5% | -31.19M▼ 13.6% | -37.16M▼ 19.1% | -30.19M▲ 18.8% | -43.71M▼ 44.8% | -39M▲ 10.8% | -37.11M▲ 0% |
| Net Margin % | -39.72% | -45.66% | -46.35% | -55.75% | -56.39% | -56.99% | -42.31% | -58.36% | -26.15% | -24.48% |
| Net Income Growth % | -42.95% | -50.05% | -20.53% | 5.48% | -13.62% | -19.13% | 18.76% | -44.78% | 10.78% | 23.49% |
| Net Income (Continuing) | -16.06M | -24.1M | -29.04M | -27.45M | -31.17M | -37.21M | -30.16M | -43.73M | -39M | -37.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.09M | 3.86M | 3.79M |
| EPS (Diluted) | -1431.28▲ 0% | -2.69▲ 99.8% | -1.87▲ 30.5% | -1.46▲ 21.9% | -1.22▲ 16.4% | -1.38▼ 13.1% | -1.05▲ 23.9% | -1.38▼ 31.4% | -0.59▲ 57.2% | -0.53▲ 0% |
| EPS Growth % | -42.95% | 99.81% | 30.48% | 21.93% | 16.44% | -13.11% | 23.91% | -31.43% | 57.25% | 58.78% |
| EPS (Basic) | -1431.28 | -2.69 | -1.87 | -1.46 | -1.22 | -1.38 | -1.05 | -1.38 | -0.59 | - |
| Diluted Shares Outstanding | 11.22K | 8.95M | 18.38M | 18.84M | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M | 69.59M |
| Basic Shares Outstanding | 11.22K | 8.95M | 18.38M | 18.84M | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M | 69.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
STIM Balance Sheet
Neuronetics, Inc. (STIM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 37.01M | 114.47M | 88.45M | 65.01M | 115.33M | 98.77M | 93.79M | 58.12M | 61.55M | 47.17M |
| Cash & Short-Term Investments | 29.15M | 104.58M | 76.59M | 50.84M | 96.34M | 71.88M | 60.58M | 19.66M | 34.36M | 13.21M |
| Cash Only | 29.15M | 104.58M | 75.71M | 48.96M | 94.14M | 70.34M | 59.68M | 19.46M | 34.13M | 13.21M |
| Short-Term Investments | 0 | 0 | 880K | 1.89M | 2.2M | 1.54M | 905K | 206K | 225K | 0 |
| Accounts Receivable | 4.27M | 5.62M | 6.57M | 7.17M | 7.78M | 13.82M | 17.84M | 24.29M | 16.89M | 16.21M |
| Days Sales Outstanding | 38.52 | 38.87 | 38.27 | 53.11 | 51.34 | 77.36 | 91.26 | 118.36 | 41.34 | 47.5 |
| Inventory | 2.47M | 2.43M | 2.77M | 3.72M | 6.56M | 8.9M | 8.09M | 4.25M | 4.33M | 4.71M |
| Days Inventory Outstanding | 93.52 | 71.32 | 65.82 | 117.52 | 205.57 | 209.79 | 150.38 | 74.8 | 20.55 | 21.17 |
| Other Current Assets | 1.12M | 1.84M | 1.83M | 2.19M | 3.09M | 2.17M | 4.77M | 6.85M | 5.97M | 13.04M |
| Total Non-Current Assets | 1.93M | 2.55M | 11.72M | 13.64M | 25.89M | 18.11M | 22.04M | 82.78M | 80M | 78.27M |
| Property, Plant & Equipment | 1.36M | 1.38M | 4.9M | 4.15M | 5.1M | 5.32M | 4.78M | 33.34M | 28.03M | 26.94M |
| Fixed Asset Turnover | 29.75x | 38.30x | 12.78x | 11.87x | 10.84x | 12.26x | 14.92x | 2.25x | 5.32x | 5.32x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.63M | 23.62M | 23.62M |
| Intangible Assets | 400K | 1M | 0 | 0 | 0 | 0 | 0 | 19.61M | 18.15M | 17.79M |
| Long-Term Investments | 0 | 0 | 1.73M | 2.33M | 1.7M | 1.22M | 661K | 86K | 249K | 775K |
| Other Non-Current Assets | 174K | 171K | 5.08M | 7.17M | 19.09M | 11.57M | 16.59M | 11.12M | 9.95M | 40.04M |
| Total Assets | 38.94M▲ 0% | 117.02M▲ 200.5% | 100.17M▼ 14.4% | 78.66M▼ 21.5% | 141.22M▲ 79.5% | 116.88M▼ 17.2% | 115.83M▼ 0.9% | 140.9M▲ 21.6% | 141.55M▲ 0.5% | 125.44M▲ 0% |
| Asset Turnover | 1.04x | 0.45x | 0.63x | 0.63x | 0.39x | 0.56x | 0.62x | 0.53x | 1.05x | 1.11x |
| Asset Growth % | 57.02% | 200.53% | -14.4% | -21.47% | 79.54% | -17.23% | -0.9% | 21.65% | 0.46% | 124.15% |
| Total Current Liabilities | 11.99M | 13.56M | 27.69M | 13.68M | 15.7M | 33.2M | 19.81M | 31.27M | 30.52M | 28.29M |
| Accounts Payable | 2.51M | 3.76M | 4.63M | 3.75M | 4.3M | 2.43M | 4.75M | 11.08M | 10.74M | 11.43M |
| Days Payables Outstanding | 95.23 | 110.14 | 109.7 | 118.43 | 134.66 | 57.36 | 88.3 | 195.05 | 51.01 | 50.27 |
| Short-Term Debt | 0 | 0 | 11.25M | 0 | 0 | 13.13M | 0 | 0 | 5.56M | 5.42M |
| Deferred Revenue (Current) | 1.97M | 2.25M | 2.23M | 2.02M | 2.5M | 1.98M | 1.62M | 974K | 753K | 3.23M |
| Other Current Liabilities | 2.72M | 2.64M | 5.72M | 5.02M | 5.09M | 11.2M | 8M | 8.95M | 13.47M | 10.6M |
| Current Ratio | 3.09x | 8.44x | 3.19x | 4.75x | 7.34x | 2.98x | 4.73x | 1.86x | 2.02x | 2.02x |
| Quick Ratio | 2.88x | 8.26x | 3.09x | 4.48x | 6.93x | 2.71x | 4.33x | 1.72x | 1.87x | 1.87x |
| Cash Conversion Cycle | 36.81 | 0.04 | -5.61 | 52.2 | 122.25 | 229.8 | 153.34 | -1.89 | 10.88 | 18.4 |
| Total Non-Current Liabilities | 219.6M | 32.42M | 24.62M | 39.48M | 40.34M | 26.63M | 61.83M | 77.84M | 84.79M | 80.09M |
| Long-Term Debt | 29.56M | 30.39M | 19.9M | 34.62M | 35.34M | 22.83M | 59.28M | 55.15M | 65.81M | 18.67M |
| Capital Lease Obligations | 0 | 0 | 2.62M | 3.12M | 3.54M | 2.97M | 2.35M | 22.69M | 18.93M | 58.23M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 187.76M | 86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61.43M |
| Total Liabilities | 231.59M | 45.98M | 52.32M | 53.16M | 56.05M | 59.82M | 81.64M | 109.1M | 115.31M | 108.38M |
| Total Debt | 29.56M | 30.39M | 34.33M | 38.34M | 39.54M | 39.74M | 62.47M | 82.63M | 90.3M | 24.09M |
| Net Debt | 409K | -74.19M | -41.38M | -10.62M | -54.6M | -30.59M | 2.8M | 63.17M | 56.17M | 10.88M |
| Debt / Equity | - | 0.43x | 0.72x | 1.50x | 0.46x | 0.70x | 1.83x | 2.60x | 3.44x | 3.44x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.90x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.40x |
| Interest Coverage | -4.72x | -5.53x | -7.67x | -5.93x | -8.45x | -9.34x | -4.57x | -5.00x | -3.74x | -2.43x |
| Total Equity | -192.65M▲ 0% | 71.04M▲ 136.9% | 47.85M▼ 32.6% | 25.49M▼ 46.7% | 85.17M▲ 234.1% | 57.06M▼ 33.0% | 34.19M▼ 40.1% | 31.8M▼ 7.0% | 26.24M▼ 17.5% | 17.06M▲ 0% |
| Equity Growth % | -8.77% | 136.88% | -32.64% | -46.73% | 234.11% | -33.01% | -40.08% | -6.99% | -17.48% | 222.49% |
| Book Value per Share | -17170.41 | 7.94 | 2.60 | 1.35 | 3.34 | 2.12 | 1.19 | 1.00 | 0.40 | 0.25 |
| Total Shareholders' Equity | -192.65M | 71.04M | 47.85M | 25.49M | 85.17M | 57.06M | 34.19M | 27.71M | 22.38M | 13.27M |
| Common Stock | 2K | 177K | 186K | 191K | 264K | 273K | 291K | 557K | 690K | 696K |
| Retained Earnings | -196.95M | -221.04M | -250.09M | -277.54M | -308.73M | -345.89M | -376.08M | -419.79M | -458.79M | -469.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.09M | 3.86M | 3.79M |
STIM Cash Flow Statement
Neuronetics, Inc. (STIM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -11.14M | -20.59M | -30.48M | -28.39M | -27.98M | -30.74M | -32.04M | -31M | -20.37M | -20.37M |
| Operating CF Margin % | -27.56% | -39.02% | -48.65% | -57.65% | -50.59% | -47.14% | -44.9% | -41.39% | -13.66% | - |
| Operating CF Growth % | -30.48% | -84.77% | -48.04% | 6.86% | 1.43% | -9.85% | -4.23% | 3.25% | 34.27% | 325.55% |
| Net Income | -16.06M | -24.1M | -29.04M | -27.45M | -31.19M | -37.16M | -30.19M | -43.73M | -39.13M | -37.11M |
| Depreciation & Amortization | 596K | 882K | 1.06M | 941K | 1.06M | 1.65M | 2.01M | 2.07M | 3.46M | 2.55M |
| Stock-Based Compensation | 496K | 1.74M | 3.43M | 4.4M | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M | 5.4M |
| Deferred Taxes | -271K | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 938K | 1.07M | 976K | 1.99M | 918K | 1.14M | 2.93M | 11.86M | 1.87M | 3.79M |
| Working Capital Changes | 3.16M | -1.58M | -6.91M | -8.28M | -6.64M | -5.12M | -14.1M | -6.81M | 6.58M | 11.6M |
| Change in Receivables | -690K | -1.35M | -950K | -597K | -3.05M | -6.66M | -8.83M | -3.73M | 3.54M | 6.17M |
| Change in Inventory | -1.07M | -435K | -306K | -945K | -3.44M | -2.59M | -1.1M | 3.15M | -395K | -570K |
| Change in Payables | 788K | 606K | 299K | -1.08M | 276K | -1.97M | 2.03M | -1.99M | -1.75M | 888K |
| Cash from Investing | -594K | -1.01M | -813K | -730K | -9.84M | 6.73M | -1.32M | -2.41M | -801K | -581K |
| Capital Expenditures | -594K | -1.01M | -813K | -730K | -2.35M | -3.27M | -2.37M | -1.47M | -801K | -582K |
| CapEx % of Revenue | 1.47% | 1.92% | 1.3% | 1.48% | 4.25% | 5.01% | 3.32% | 1.96% | 0.54% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.55M | 0 | 25K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 2.61M | 0 | -7.81M | 10M | 1.05M | 1.61M | 31K | 11K |
| Cash from Financing | 23.84M | 97.04M | 2.42M | 2.37M | 83.01M | 207K | 22.7M | -6.81M | 35.85M | 16.87M |
| Debt Issued (Net) | 10M | 0 | 0 | 2.5M | 0 | 0 | 23.8M | -2.52M | 9.62M | 4.62M |
| Equity Issued (Net) | 14.82M | 100M | 0 | 0 | 80.97M | 0 | 0 | 0 | 26.82M | 7.85M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -980K | -2.96M | 2.42M | -131K | 2.03M | 207K | -1.1M | -4.29M | -594K | 4.41M |
| Net Change in Cash | 12.11M▲ 0% | 75.44M▲ 523.1% | -28.88M▼ 138.3% | -26.75M▲ 7.4% | 45.18M▲ 268.9% | -23.8M▼ 152.7% | -10.66M▲ 55.2% | -40.22M▼ 277.2% | 14.68M▲ 136.5% | -2.26M▲ 0% |
| Free Cash Flow | -11.74M▲ 0% | -21.6M▼ 84.0% | -31.3M▼ 44.9% | -29.12M▲ 6.9% | -30.34M▼ 4.2% | -34.01M▼ 12.1% | -34.41M▼ 1.2% | -32.46M▲ 5.7% | -21.18M▲ 34.8% | -3.96M▲ 0% |
| FCF Margin % | -29.03% | -40.93% | -49.95% | -59.13% | -54.85% | -52.15% | -48.22% | -43.35% | -14.2% | -2.61% |
| FCF Growth % | -32.41% | -84.03% | -44.87% | 6.95% | -4.18% | -12.1% | -1.17% | 5.65% | 34.77% | 89.37% |
| FCF per Share | -1046.17 | -2.41 | -1.70 | -1.55 | -1.19 | -1.26 | -1.20 | -1.02 | -0.32 | -0.32 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.85x | 1.05x | 1.03x | 0.90x | 0.83x | 1.06x | 0.71x | 0.52x | 0.11x |
| Interest Paid | 0 | 0 | 0 | 3.89M | 0 | 3.54M | 4.79M | 6.51M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STIM Key Ratios
Neuronetics, Inc. (STIM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -33.92% | -48.86% | -74.86% | -56.37% | -52.25% | -66.17% | -132.47% | -134.39% | -139.83% |
| Return on Invested Capital (ROIC) | - | - | -1215.25% | -156.8% | -90.97% | -92.33% | -72.23% | -39.29% | -26.58% | -26.58% |
| Gross Margin | 76.18% | 76.42% | 75.44% | 76.54% | 78.93% | 76.26% | 72.47% | 72.32% | 48.48% | 47.96% |
| Net Margin | -39.72% | -45.66% | -46.35% | -55.75% | -56.39% | -56.99% | -42.31% | -58.36% | -26.15% | -24.48% |
| Debt / Equity | - | 0.43x | 0.72x | 1.50x | 0.46x | 0.70x | 1.83x | 2.60x | 3.44x | 3.44x |
| Interest Coverage | -4.72x | -5.53x | -7.67x | -5.93x | -8.45x | -9.34x | -4.57x | -5.00x | -3.74x | -2.43x |
| FCF Conversion | 0.69x | 0.85x | 1.05x | 1.03x | 0.90x | 0.83x | 1.06x | 0.71x | 0.52x | 0.11x |
| Revenue Growth | 18.13% | 30.53% | 18.72% | -21.41% | 12.32% | 17.89% | 9.42% | 4.96% | 99.17% | 69.52% |
STIM SEC Filings & Documents
Neuronetics, Inc. (STIM) SEC filings — annual & quarterly reports (10-K, 10-Q)
STIM Frequently Asked Questions
Neuronetics, Inc. (STIM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neuronetics, Inc. (STIM) reported $151.6M in revenue for fiscal year 2025. This represents a 343% increase from $34.2M in 2016.
Neuronetics, Inc. (STIM) grew revenue by 99.2% over the past year. This is strong growth.
Neuronetics, Inc. (STIM) reported a net loss of $37.1M for fiscal year 2025.
Dividend & Returns
Neuronetics, Inc. (STIM) has a return on equity (ROE) of -134.4%. Negative ROE indicates the company is unprofitable.
Neuronetics, Inc. (STIM) had negative free cash flow of $4.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More STIM
Neuronetics, Inc. (STIM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates